Solid Biosciences at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Solid Biosciences brings 7 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for muscular dystrophy and heart disease, including muscle integrity results from its Duchenne candidate. Other strands cover capsid transduction, raising production yield in HEK293 cells and clearing pre-existing antibodies before dosing.
| Organization | ESGCT 2026 Attendance |
|---|---|
Solid Biosciences Charlestown, Massachusetts | |
Develops AAV gene therapies for neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy, plus capsid and manufacturing technology. | Poster Wed Oct 28 1:30pm–3:30pm Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity Poster Wed Oct 28 1:30pm–3:30pm SGT-003 gene therapy restores DAPC stability and improves muscle integrity in Duchenne muscular dystrophy Poster Wed Oct 28 1:30pm–3:30pm Transcriptomic profiling identifies G2/M cell cycle modulation as a strategy to enhance rAAV production Poster Thu Oct 29 2:00pm–4:00pm Boosting rAAV yield and quality in HEK293 cells through multi‑mechanism strategies Poster Thu Oct 29 2:00pm–4:00pm Development and implementation of a high yield and scalable manufacturing process for Adeno-associated virus (AAV) production Poster Thu Oct 29 2:00pm–4:00pm Mechanism of improved POLARIS-101TM capsid transduction Poster Thu Oct 29 2:00pm–4:00pm Successful Polaris‑101TM transduction of multiple tissues after depletion of preexisting antibodies using a novel IgG-degrading enzyme |
Instantly find 20 buyers from Solid Biosciences
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction